Gainers

• Cue Biopharma (NASDAQ:CUE) shares increased by 69.9% to $0.5 during Friday's regular session. The company's market cap stands at $28.6 million.
• Plus Therapeutics (NASDAQ:PSTV) shares moved upwards by 32.14% to $5.18. The company's market cap stands at $26.8 million.
• Tempest Therapeutics (NASDAQ:TPST) shares rose 30.37% to $2.06. The company's market cap stands at $22.6 million.
• Zentalis Pharmaceuticals (NASDAQ:ZNTL) stock rose 29.61% to $5.73. The market value of their outstanding shares is at $313.5 million.
• Treace Medical Concepts (NASDAQ:TMCI) shares moved upwards by 20.58% to $1.84. The market value of their outstanding shares is at $97.4 million.
• Organon (NYSE:OGN) stock moved upwards by 20.47% to $8.32. The market value of their outstanding shares is at $1.7 billion.

Losers

• CDT Equity (NASDAQ:CDT) shares declined by 23.8% to $4.49 during Friday's regular session. The market value of their outstanding shares is at $27.8 million.
• Replimune Group (NASDAQ:REPL) stock declined by 19.46% to $4.76. The market value of their outstanding shares is at $463.6 million.
• Harvard Bioscience (NASDAQ:HBIO) stock fell 16.39% to $4.49. The company's market cap stands at $24.0 million.
• Insight Molecular (NASDAQ:IMDX) stock declined by 16.2% to $2.67. The company's market cap stands at $102.2 million.
• Profusa (NASDAQ:PFSA) shares decreased by 16.09% to $0.88. The company's market cap stands at $1.4 million.
• Virax Biolabs Group (NASDAQ:VRAX) shares decreased by 15.66% to $0.11. The market value of their outstanding shares is at $1.0 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.